Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908310 · ClinicalTrials.gov registry record · Phase 4
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
A Phase 4 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 213
- Enrollment target
NCT00908310: Completed Phase 4 study, sponsored by GE Healthcare.
NCT00908310 is a Phase 4 study that has completed, run by GE Healthcare. The registered enrollment target is 213 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00908310, a Phase 4 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 213 participants
- Enrollment target
Study Summary
This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.
Primary Outcome
Capture of safety information in moderate renal insufficiency patients undergoing routine contrast-enhanced MRI with administration of OMNISCAN.
Interventions
- DRUG Omniscan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
What the finished NCT00908310 record still lists
NCT00908310 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which Omniscan is the first listed.
NCT00908310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00908310 about?
NCT00908310 is a clinical study titled "Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)". This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.
What is the current status of trial NCT00908310?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 213 participants. The study started on 2009-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00908310?
The interventions under investigation include: Omniscan (DRUG).
Who is sponsoring clinical trial NCT00908310?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00908310's enrollment target sits among peer trials
213 396th of 2000 higher than 1,605 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia